Salvador Cabrera Figueroa

Summary

Affiliation: Universidad Austral de Chile
Country: Chile

Publications

  1. doi request reprint The convergence of therapeutic drug monitoring and pharmacogenetic testing to optimize efavirenz therapy
    Salvador Cabrera Figueroa
    Pharmacy Service, University Hospital of Salamanca, Salamanca, Spain
    Ther Drug Monit 32:579-85. 2010
  2. ncbi request reprint Pharmacogenetic analysis of SNPs in genes involved in the pharmacokinetics and response to lopinavir/ritonavir therapy
    E López Aspiroz
    Pharmacy Service, University Hospital of Salamanca, Salamanca, Spain
    Curr Drug Metab 14:729-37. 2013
  3. doi request reprint Long-term efficacy and safety of efavirenz dose reduction to 200 mg once daily in a Caucasian patient with HIV
    Salvador Cabrera Figueroa
    Pharmacy Service, University Hospital of Salamanca, Salamanca, Spain
    Clin Drug Investig 30:405-11. 2010
  4. doi request reprint Impact of pharmacogenetics on CNS side effects related to efavirenz
    Almudena Sánchez Martín
    Pharmacy Service, University Hospital of Salamanca, Salamanca, Spain
    Pharmacogenomics 14:1167-78. 2013
  5. doi request reprint Population pharmacokinetics of lopinavir/ritonavir (Kaletra) in HIV-infected patients
    Elena López Aspiroz
    Pharmacy Service, University Hospital of Salamanca, Salamanca, Spain
    Ther Drug Monit 33:573-82. 2011

Collaborators

  • Almudena Sánchez Martín
  • E López Aspiroz
  • Elena López Aspiroz
  • Liliana Porras Hurtado
  • Angel Carracedo Álvarez
  • A Dominguez-Gil Hurle
  • Raquel Cruz Guerrero
  • G L Porras Hurtado
  • - The Tormes Team
  • R Cruz Guerrero
  • Alfonso Domínguez Gil Hurlé
  • A Carracedo
  • Esteban Ribera Pascuet
  • Alfonso Domínguez-Gil Hurlé
  • María José García Sánchez
  • Dolores Santos Buelga
  • Rosa María López Galera

Detail Information

Publications5

  1. doi request reprint The convergence of therapeutic drug monitoring and pharmacogenetic testing to optimize efavirenz therapy
    Salvador Cabrera Figueroa
    Pharmacy Service, University Hospital of Salamanca, Salamanca, Spain
    Ther Drug Monit 32:579-85. 2010
    ..As genotype screens become cheaper, and in combination with TDM, adjusting dosages in the light of genetic polymorphisms will become a reality...
  2. ncbi request reprint Pharmacogenetic analysis of SNPs in genes involved in the pharmacokinetics and response to lopinavir/ritonavir therapy
    E López Aspiroz
    Pharmacy Service, University Hospital of Salamanca, Salamanca, Spain
    Curr Drug Metab 14:729-37. 2013
    ....
  3. doi request reprint Long-term efficacy and safety of efavirenz dose reduction to 200 mg once daily in a Caucasian patient with HIV
    Salvador Cabrera Figueroa
    Pharmacy Service, University Hospital of Salamanca, Salamanca, Spain
    Clin Drug Investig 30:405-11. 2010
    ..This also resulted in a reduction in ADEs. At present, the patient's CD4+ levels remain stable, his viral load continues to be undetectable and the mean efavirenz C(min,ss) is within the therapeutic range (2.7 mg/L)...
  4. doi request reprint Impact of pharmacogenetics on CNS side effects related to efavirenz
    Almudena Sánchez Martín
    Pharmacy Service, University Hospital of Salamanca, Salamanca, Spain
    Pharmacogenomics 14:1167-78. 2013
    ..This article evaluates which genetic factors are involved in CNS toxicity related to long-term treatment with efavirenz (EFV) standard doses and their relationship with plasma concentrations...
  5. doi request reprint Population pharmacokinetics of lopinavir/ritonavir (Kaletra) in HIV-infected patients
    Elena López Aspiroz
    Pharmacy Service, University Hospital of Salamanca, Salamanca, Spain
    Ther Drug Monit 33:573-82. 2011
    ..Therefore, it is important to increase our knowledge about factors that determine interpatient variability in LPV pharmacokinetics (PK)...